GLP-1 weight loss results at 14 weeks: what's real vs. hype

What did @prettygirlglaze actually say?

She described a 14-week weight loss journey using what she called a "GOPGIP shot" at 37.5 units, which from context appears to be a compounded tirzepatide formulation. She said she was taking "17 mg of the turcetetite plus NAD" and walked viewers through her injection technique, including the air-displacement method to reduce bubbles when drawing from a vial.

She also mentioned having Hashimoto's disease, noted she feels sick when her daughter gets sick, and showed her stomach transformation at 14 weeks. The injection site she demonstrated was the abdomen, while acknowledging others use arms or thighs. Her tone was casual and personal, framed as a progress update rather than medical instruction, though the step-by-step injection walkthrough clearly functions as one.

Does the science back this up?

The weight loss results are plausible. Tirzepatide's clinical data is actually pretty impressive, though individual results vary enormously and 14-week outcomes depend heavily on starting weight, dose, and adherence.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found that tirzepatide at 15 mg produced an average weight reduction of 20.9% over 72 weeks in adults with obesity. Fourteen weeks is early in that curve, so meaningful loss is expected but peak results are not yet reached. The injection technique she demonstrated, specifically injecting air into the vial before drawing medication, is a standard practice to equalize pressure and reduce air bubbles. That part checks out. Subcutaneous abdominal injection is also a clinically validated site for this drug class. The NAD add-in she mentioned is a different story, covered below.

What did they get wrong (or right)?

Several things need unpacking here, some minor, some worth flagging.

The medication name

She consistently mispronounced the drug, calling it "GOPGIP" and "turcetetite." The actual drug appears to be tirzepatide (brand names Zepbound or Mounjaro), a dual GIP/GLP-1 receptor agonist. This is a communication issue, not a safety one, but mispronunciation at scale contributes to consumer confusion about what they're actually taking.

The NAD addition

She said she takes "17 mg of the turcetetite plus NAD." Compounded tirzepatide is sometimes combined with NAD+ (nicotinamide adenine dinucleotide) at compounding pharmacies, but this combination has no randomized controlled trial data supporting its use or safety profile. The FDA has not evaluated this stack. Claiming NAD enhances outcomes is not supported by current evidence, and viewers should know that "plus NAD" is a compounding choice, not a studied protocol.

Hashimoto's and immune function

She said Hashimoto's disease causes her immune system to be "really low." This is inaccurate. Hashimoto's is an autoimmune condition, meaning the immune system is dysregulated and overactive against thyroid tissue, not suppressed. Patients with Hashimoto's are not clinically immunocompromised. This is a common misconception but worth correcting.

The injection technique

The air-displacement draw method she demonstrated is legitimate. Credit where it's due.

What should you actually know?

If you're considering a GLP-1 or dual GIP/GLP-1 agonist, the clinical data is real and the results can be significant. But there are serious gaps between what TikTok shows and what clinical practice looks like.

First, compounded tirzepatide is not equivalent to FDA-approved Zepbound or Mounjaro. The FDA has warned about quality and dosing inconsistencies in compounded versions (FDA Drug Safety Communication, 2024). The "37.5 units" dosing she references is a volume measurement from a vial of unknown concentration, not a standardized dose. Viewers should not interpret her dose as applicable to themselves.

Second, adding NAD+ to a compounded peptide is not a studied protocol. It may seem like a wellness upgrade, but there is no peer-reviewed evidence that it improves tirzepatide outcomes or that the combination is safe long-term.

Third, Hashimoto's disease affects thyroid function and involves autoimmune activity. It does not cause immunosuppression in the clinical sense. If you have Hashimoto's and are starting a GLP-1 therapy, the relevant conversation is with your endocrinologist about how thyroid function interacts with weight loss, not about immune vulnerability.

Results at 14 weeks are encouraging but early. The SURMOUNT-1 data shows the weight loss curve continues well past this point, and many patients see plateau effects that require dose adjustments. Staying consistent, as she recommends, is actually well-supported by the data.